He Huang1, Yu Liu1, Yawei Xu2, Zulu Wang3, Yigang Li4, Kejiang Cao5, Shu Zhang6, Yanzong Yang7, Xinchun Yang8, Dejia Huang9, Bo Yu10, Xi Su11, Liqun Wu12, Congxin Huang13. 1. Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, People's Republic of China; Cardiovascular Research Institute of Wuhan University, Wuhan, People's Republic of China; Hubei Key Laboratory of Cardiology, Wuhan, People's Republic of China. 2. Department of Cardiology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, People's Republic of China. 3. Department of Cardiology, General Hospital of Shenyang Military Region, Shenyang, People's Republic of China. 4. Department of Cardiology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China. 5. Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People's Republic of China. 6. State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China. 7. Department of Cardiology, First Affiliated Hospital of Dalian Medical University, Dalian, People's Republic of China. 8. Department of Cardiology, Chaoyang Hospital, Capital Medical University, Beijing, People's Republic of China. 9. Department of Cardiology, West China Hospital, Sichuan University, Chengdu, People's Republic of China. 10. Department of Cardiology, The Second Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China. 11. Department of Cardiology, Wuhan Asian Heart Hospital, Wuhan, People's Republic of China. 12. Department of Cardiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China. 13. Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, People's Republic of China; Cardiovascular Research Institute of Wuhan University, Wuhan, People's Republic of China; Hubei Key Laboratory of Cardiology, Wuhan, People's Republic of China. Electronic address: huangcongxin@vip.163.com.
Abstract
OBJECTIVES: The authors sought to assess the clinical outcomes of left atrial appendage (LAA) closure with the LAmbre closure system in patients with nonvalvular atrial fibrillation (NVAF). BACKGROUND: Over 90% of thrombi are located in the LAA in NVAF patients. METHODS: A prospective, multicenter study was conducted in 153 NVAF patients with CHADS2 score ≥1. RESULTS: The LAA was successfully occluded in 152 patients. Serious complications occurred in 5 patients. During the 12-month follow-up, ischemic stroke occurred in 2 patients, 1 patient had incomplete LAA sealing, and there was no device embolization. CONCLUSIONS: LAA closure with the LAmbre device shows encouraging results for stroke prevention.
OBJECTIVES: The authors sought to assess the clinical outcomes of left atrial appendage (LAA) closure with the LAmbre closure system in patients with nonvalvular atrial fibrillation (NVAF). BACKGROUND: Over 90% of thrombi are located in the LAA in NVAF patients. METHODS: A prospective, multicenter study was conducted in 153 NVAF patients with CHADS2 score ≥1. RESULTS: The LAA was successfully occluded in 152 patients. Serious complications occurred in 5 patients. During the 12-month follow-up, ischemic stroke occurred in 2 patients, 1 patient had incomplete LAA sealing, and there was no device embolization. CONCLUSIONS: LAA closure with the LAmbre device shows encouraging results for stroke prevention.
Authors: Muhammad Ali; Angelos G Rigopoulos; Mammad Mammadov; Abdelrahman Torky; Andrea Auer; Marios Matiakis; Elena Abate; Constantinos Bakogiannis; Stergios Tzikas; Boris Bigalke; Daniel Sedding; Michel Noutsias Journal: BMC Cardiovasc Disord Date: 2020-02-12 Impact factor: 2.298